| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, Former 10% Owner
2 companies
Clarke John K serves as a Director at ATYR and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 9 sells. Those positions are worth an estimated $892K at current prices.
The biggest single holding is ALNY (~$892K) as Director. The recent filings there lean toward selling, a net 15,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2021 | ATYR Atyr Pharma Inc | Director | Sell | 2,500 | $4.34 | $10,850.00 | -2.3% | +1.6% | -32.6% | |
| Sep 2, 2020 | ATYR Atyr Pharma Inc | Director | Sell | 7,360 | $4.01 | $29,512.60 | -6.2% | - | - | |
| Aug 27, 2020 | ATYR Atyr Pharma Inc | Director | Sell | 7,640 | $4.15 | $31,700.80 | -6.1% | - | - | |
| May 31, 2018 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE | 15,000 | $100.31 | $1,504,677.90 | -62.8% | - | - |